Experts are rapidly investigating retatrutide, a novel treatment developed by Eli Lilly, as a possible advance in weight loss . Distinct from many earlier approaches, retatrutide is a twin-action receptor targeting both GLP-1 and GIP, substances that impact hunger and glucose balance. Preliminary c